Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01797185 · ClinicalTrials.gov registry record · Phase 3
Safety Study of SPARC1104
A Phase 3 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT01797185 is a Phase 3 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 375 participants.
The verdict
NCT01797185, a Phase 3 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
Interventions
- DRUG SPARC1104 modified dose regimen I
- DRUG SPARC1104 modified dose regimen II
- DRUG SPARC1104 modified dose regimen III
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2013-04-09 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01797185
The ClinicalTrials.gov registry entry for NCT01797185 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SPARC1104 modified dose regimen I is the first listed.
NCT01797185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01797185 about?
NCT01797185 is a clinical study titled "Safety Study of SPARC1104". Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
What is the current status of trial NCT01797185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2013-04-09. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01797185?
The interventions under investigation include: SPARC1104 modified dose regimen I (DRUG), SPARC1104 modified dose regimen II (DRUG), SPARC1104 modified dose regimen III (DRUG).
Who is sponsoring clinical trial NCT01797185?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.